Drugs / BAT6021
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05120375 | Feb 2022 → Apr 2023 | neoplasm | Bio-Thera Solutions | Terminated | No outcome recorded |
| Phase 1 | NCT05073484 | Oct 2021 → Mar 2023 | — | Bio-Thera Solutions | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT6021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05073484 ↗ |
| Modality | Monoclonal antibody | “Recombinant humanized monoclonal antibody against TIGIT injection” NCT05120375 ↗ |
| Route | Intravenous | “Ⅳ infusions” NCT05120375 ↗ |
| Target | TIGIT | “Recombinant humanized monoclonal antibody against TIGIT injection” NCT05120375 ↗ |